Medicus Pharma

MDCX · NASDAQ

$2.50−$0.12 (−4.58%)TodayMarket closed · Oct 23, 7:54 PM ET

Prev close $2.62

MDCX analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $207.82 (+8213.0% upside)

Low: $15.15
Now: $2.50
High: $472.50

Upgrades and downgrades

The latest rating actions, newest first

MDCX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
D. Boral Capital	Apr 20, 2026	Maintains	Buy	$9.00	28%
D. Boral Capital	Mar 19, 2026	Maintains	Buy	$27.00	28%
D. Boral Capital	Mar 9, 2026	Maintains	Buy	$27.00	28%
D. Boral Capital	Dec 15, 2025	Maintains	Buy	$27.00	28%
D. Boral Capital	Nov 17, 2025	Maintains	Buy	$27.00	28%
D. Boral Capital	Nov 13, 2025	Maintains	Buy	$27.00	28%
D. Boral Capital	Oct 29, 2025	Maintains	Buy	$27.00	28%

The case for and against

Updated Sep 15, 2026

Bull case

Medicus Pharma is focusing on developing a non-surgical option for treating recurring basal cell carcinomas in Gorlin Syndrome patients, with potential market exclusivity and regulatory benefits. The company has shown promising Phase 2 trial results, with the potential to further strengthen their regulatory strategy and attract potential partnerships. There are risks involved, including clinical, financial, and market share risks, but the company's unique approach and potential for long-term value make it a positive investment opportunity.

Bear case

Medicus Pharma is at high risk, as they have a significant amount of clinical and regulatory risk due to their focus on novel and unproven therapeutic assets. Their potential partnerships and financials are also at risk, and their market share may be impacted by unknown factors. Additionally, there are concerns over legal and intellectual property risks, which could be detrimental to their success in the competitive life sciences industry.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.